Source: International Congress 2015 – The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Huib A.M. Kerstjens (Groningen, Netherlands), Eric D. Bateman (Cape Town, South Africa), A.M. Kerstjens (Groningen, Netherlands), J. Mark Fitzgerald (Vancouver, Canada), Kim Lavoie (Montréal, Canada). The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options. International Congress 2015 – The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options

Member's Comments

Somnath Bhattacharya - 17.11.2015 18:11
nice

Related content which might interest you: Treatment of moderate persistent asthma: new options Source: Annual Congress 2007 - Pharmacological treatment of mild to moderate persistent asthma: new approaches Year: 2007 Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation Source: Eur Respir J, 58 (2) 2003393; 10.1183/13993003.03393-2020 Year: 2021 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Filling the gaps: future treatment options for mild asthma Source: International Congress 2018 – The complexities of managing mild asthma Year: 2018 Managing asthma patients: which outcomes matter? Source: Eur Respir Rev 2008; 17: 53-61 Year: 2008 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Adherence to asthma treatment: Can it be improved in general practice? Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Evaluating inhalation technique among COPD patients comparing 4 different methods Source: International Congress 2017 – Inhalers and their use Year: 2017 Use of alternative therapies in patients with asthma and COPD: is there any difference? Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005 Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study) Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Omalizumab in children with severe asthma (SA): Which parameters improve after a 16 week trial? Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012